CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, ...

Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total RevenuesQ4 ...

Catalyst Pharmaceuticals, Inc. CPRX announced positive top-line results from a second phase III study of Firdapse. As the lead pipeline candidate of the company, Firdapse is being developed for the ...

What Tools Were Used in the Studies for Lambert-Eaton Myasthenic Syndrome (LEMS)? Before describing how Firdapse was studied, it is important to understand the tools that were used in the studies.

CORAL GABLES, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, ...

We issued an updated research report on Catalyst Pharmaceuticals Inc. CPRX on Sep 7, 2020. Catalyst’s share price has declined 17.9% compared with the industry’s decline of 9% in the year so far. The ...

Catalyst Pharmaceuticals CPRX, along with its licensor, SERB, recently announced entering into a settlement agreement with Lupin Pharmaceuticals regarding the Firdapse (amifampridine)patent litigation ...

The FDA’s 2019 approval of Jacobus Pharmaceutical Co. Inc.’s Ruzurgi to treat children ages 6 to 17 with Lambert-Eaton myasthenic syndrome must be set aside because it violated the Orphan Drug Act in ...

Catalyst, a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines, announced that the company and its licensor SERB have entered into an ...

Catalyst Pharmaceuticals CPRX, along with its licensor, SERB, recently announced entering into a settlement agreement with Lupin Pharmaceuticals regarding the Firdapse (amifampridine)patent litigation ...

Catalyst Pharmaceuticals, Inc.’s CPRX lead drug, Firdapse (amifampridine), is approved in the United States and Europe for the treatment of adult patients with Lambert-Eaton myasthenic syndrome (“LEMS ...

Management reaffirmed full year 2025 revenue guidance of $545 million to $565 million. Product-specific guidance includes $355 million to $360 million for FIRDAPSE, $100 million to $110 million for ...